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Abstract
The objective of the ACGT (Advancing Clinico-Genomic Trials on Cancer: Open Grid Services for improving
Medical Knowledge Discovery, www.eu-acgt.org) project that has recently concluded successfully was the develop-
ment of a semantically rich infrastructure facilitating seamless and secure access and analysis, of multi-level clinical
and genomic data enriched with high-performing knowledge discovery operations and services in support of multi-
centric, post-genomic clinical trials. In this paper we describe the way the ACGT consortium has approached impor-
tant challenges in the design and the execution of the clinical trials such as the issues of data integration, semantics
based data fusion, data processing and knowledge extraction, privacy and security, etc. Furthermore we provide a
number of key “lessons learned” during the process and give directions for further developments in the future.
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1. Introduction
Recent advances in methods and technologies in molecular biology have resulted in an explosion of information
and knowledge about cancer and its treatment. As a result, our ability to characterize and understand the various
forms of cancer is growing exponentially. Information arising from post-genomics research and combined genetic and
clinical trials on one hand, and advances from high-performance computing and informatics on the other, is rapidly
providing the medical and scientiﬁc community with an enormous opportunity to improve prognosis of patients with
cancer by individualizing treatment. To achieve this goal, a unifying platform is needed that has the capacity to
process this huge amount of multi-level and heterogeneous data in a standardized way. Multi-level data collection
within clinico-genomic trials and interdisciplinary analysis by clinicians, molecular biologists and others involved in
life science is mandatory to further improve the outcome of cancer patients. It is essential to merge the research results
of biomolecular ﬁndings, imaging studies and clinical data of patients and to enable users to easily join, analyze and
share even great amounts of data.
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An important challenge in carrying out post-genomic bio-medical research is therefore to eﬃciently manage and
retrieve all relevant data from many heterogeneous sources. A post-genomic clinical trial involves the collection,
storage and management of a wide variety of data, including: clinical data collected on Case Report Forms (e.g.
symptoms, histology, administered treatment, treatment response), imaging data, genomic data, pathology data and
other lab data. Next to that, access to many external sources of data and knowledge is required. These store informa-
tion about gene and protein sequences, pathways, genomic variation, microarray experiments, medical literature, etc.
Seamless access to all these data repositories would greatly facilitate research.
Furthermore the state-of the-art clinical research requires an array of data manipulation, visualization, statistical,
and knowledge extraction tools in order to gain insight into the meaning of the data and answer the speciﬁc research
questions posed. To provide a functional and user-friendly suite of tools in a coherent platform it is of utmost impor-
tance that the development of such a platform is user-driven and evaluated by end users right from the planning and
development phase. Such tools and software should also be based on the user’s needs and have to be in accordance
with ethical and legal requirements of the European Community.
The ACGT (Advancing Clinico-Genomic Trials on cancer: Open Grid Services for improvingMedical Knowledge
Discovery)[1] was an Integrated Project (IP) funded in the 6th Framework Program of the European Commission
that aimed at providing solutions to the challenges described above. The ACGT technological platform is based
on an ontology-driven, semantic grid services infrastructure that enables the eﬃcient execution of discovery-driven
analytical workﬂows in the context of multi-centric, post-genomic clinical trials. The ultimate objective of the ACGT
project was the development of a secure semantic grid services infrastructure which will (a) facilitate seamless and
secure access to heterogeneous, distributed multilevel databases; (b) provide a range of semantically rich re-usable,
open tools for the analysis of such integrated, multilevel clinico-genomic data; (c) achieve these results in the context
of discovery-driven (eScience) workﬂows and dynamic VOs; and (d) fulﬁll these objectives while complying with
existing ethical and legal regulations. In this paper we describe the way the ACGT consortium approaches important
challenges in the design and the execution of the clinical trials such as the issues of data integration, semantics based
data fusion, data processing and knowledge extraction, privacy and security, etc. Furthermore we provide a number
of key “lessons learned” during the process and give directions for further developments in the future.
1.1. Architecture and key components
Because of the complexity and the diversity of the user requirements and the biomedical domain in general a
multidisciplinary and multi-paradigm approach was followed, according to the following technologies and standards:
Service Oriented Architecture (Web Services [2]), the Grid [3], and the Semantic Web [4]. These underlying technolo-
gies work complementary to each other, providing their beneﬁts in diﬀerent aspects of the technological infrastructure.
The Grid provides the computational and data storage infrastructure, the general security framework, the virtual or-
ganization abstraction and relevant user management mechanisms etc. The machine to machine communication is
performed via XML programmatic interfaces over web transport protocols, which are commonly referred as Web Ser-
vices interfaces. Finally the Semantic Web adds the universal data modeling technology in terms of the RDF abstract
model, the knowledge representation mechanisms through the means of OWL ontologies, the implementation-neutral
query facilities with the SPARQL query language and the associated query interfaces, etc.
The adopted architecture for ACGT is shown in Fig. 1. A layered approach has been followed for providing
diﬀerent levels of abstraction and a classiﬁcation of functionality into groups of homologous software entities. In this
approach we consider the security services and components to be pervasive throughout the ACGT platform, so as to
cater both for the user management, access rights management and enforcement, and trust bindings that are facilitated
by the grid and domain speciﬁc security requirements like pseudonymization.
The sensitivity of the patient data requires a strong security framework to provide enough safety nets in order to
maintain privacy, conﬁdentiality, and integrity. The grid middleware already supports much of the necessary infras-
tructure, in terms of certiﬁcate based Grid Security Infrastructure (GSI)[5], the Virtual Organization (VO) abstraction
and the user credential management, and the Grid Authorization Services (GAS). In ACGT this “system level” se-
curity is complemented by “domain speciﬁc” mechanisms like pseudomymization that permits the identiﬁcation of
patient speciﬁc information without revealing the true person identity [6]. All data is anomymized before their entry
in the ACGT domain and, even during their analysis, all the processing tasks are audited and authorized based on the
end users’ identity and access rights as speciﬁed in the context of a clinical trial.
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Fig. 1: The ACGT Architecture
Apart from the security requirements, the Grid infrastructure and other services are located in the ﬁrst (lowest) two
layers: the Common Grid Layer and the Advanced Grid Middleware Layer. The upper layer is where the user access
services, such as the ACGT Portal and the visualization tools, reside. Finally, the Bioinformatics and Knowledge
Discovery Services are the workhorse of ACGT and the corresponding layer is where the majority of the ACGT
speciﬁc services lie. Some of the most important components and services of this layer are described below.
1.1.1. The ACGT Master Ontology on Cancer
The ACGT Master Ontology on Cancer (ACGT MO) has been developed with the goal of building a consistent
semantic framework for describing the domain of post-genomic clinical trials on cancer [7]. This framework is the
basis of the semantic interoperability to connect the diﬀerent services and data sources in the ACGT Platform: it is the
“lingua franca” for the integration, analysis, and synthesis of data. It is written in OWL-DL – which allows automatic
reasoning e.g. for consistency checking – and contains more than 1600 classes and near 300 properties.
1.1.2. Clinical Trial Builder: ObTima
ObTiMA is an ontology-based system for creating and conducting clinical trials on cancer [8]. The system includes
a graphical Trial Builder and facilitates the trial chairman in the design of the Case Report Forms (CRFs) to be used
for each treatment step. The design of the CRFs is based on the ACGT MO which means that ontology compliance is
“built in” and interoperability or syntactic transformation is to great extent guaranteed. The data collected in the trial
is stored in trial databases in the Patient Data Management System, which is the other component of ObTiMA that is
setup automatically in such a way that a medical clinician can collect the patient data during the trial (Fig. 2).
1.1.3. Data Access Services
The Data Access Layer of the ACGT platform consists of the Database Wrappers and the Semantic Mediator [9].
The database wrappers deal with the syntactic heterogeneities, oﬀering a uniform query interface (SPARQL) to data
resources. On the other hand the Semantic Mediator tackles the semantic heterogeneities – i.e. oﬀering a common
data model for accessing the data resources exposed by the wrappers and performing query translation from the
global schema to the local schemata of the integrated databases. The ACGT MO has been adopted as the global
model exposed to the clients of the Data Access Layer through a single SPARQL endpoint. The Semantic Mediator
translates the query expressed in terms of the Master Ontology to the language of the Data Access Service. Fig. 3
shows an example of a simple query called “Patient Weights” before and after the mediation process.
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Fig. 2: The components of ObTiMA
1.1.4. KDD Tools
The ACGT Platform comprises a series of knowledge discovery tools for analyzing and extracting useful infor-
mation from data collected in a clinical trial. With an abundance of such tools available freely it was decided that the
core question does not relate with the development of new tools, but rather with how to seamlessly integrate existing
toolkits.
The R language has been adopted as the prime tool for carrying out statistical analysis of the data. The GridR
tool [10] allows to seamlessly execute R jobs and addresses the needs of the users by enabling them to use their
standard analysis tools in the context of large, distributed eScience systems. In ACGT GridR plays a dual role: on
one hand it can be used interactively, giving the users access to the whole ACGT environment, on the other hand it
is deployed as a data-analysis service exposing a Web Service interface for the execution of scripts incorporated in
scientiﬁc workﬂows. This facilitates the eﬃcient development, execution, and re-use of analytical solution without
the need for any knowledge about the underlying architecture on the side of the analyst. Additionally integration
Fig. 3: (a) A “Patient Weights” query for the Semantic Mediator; (b) The query after the translation as submitted to a trial database
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with the Biomoby open source registry of tools [11] allows the use of even a larger set of domain speciﬁc analyses to
performed in the context of the ACGT supported clinical trials.
1.1.5. The ACGT Workﬂow environment
To assist bioinformaticians in building their complex scientiﬁc workﬂows, a Workﬂow Editor and Enactment
Environment has been implemented [12]. This environment is accessible through the ACGT Portal and includes a
suite of tools that allow users to combine diﬀerent web services into complex workﬂows. An intuitive user interface
permits searching registered services – e.g. GridR scripts – and retrieving data through the Data Access Layer. These
elements can then be combined and orchestrated to produce the expected workﬂow. The designed workﬂows can be
stored in a user’s speciﬁc area and later retrieved and edited. Workﬂows are executed on a remote machine or even
in a cluster of machines in the Grid so there is no burden imposed on the user’s local machine. The publication,
annotation, and sharing of the workﬂows are also supported so that the user community can exchange information
beneﬁtting from each other’s research.
2. Evaluation in an exemplary scenario
Evaluation of the ACGT platform has been done in the context of clinically oriented data analysis scenarios. One
such scenario is the so called “Multi Center Multi Platform” (MCMP) scenario, that aimed at demonstrating the utility
of the platform as an information system to exploit data in the context of a clinical trial. In this scenario biopsies are
collected from patients registered in two centers and each center is using a diﬀerent microarray platform, namely
Aﬀymetrix and Illumina, to measure genes expression in the samples. In addition, the classical clinical parameters
associated to each patient are available in a trial database. This speciﬁes a multi-centric and multi-platform study,
with only one microarray per patient. All patient private data were anonymized prior to their integration in the ACGT
environment. The whole scenario has been realized by the means of a scientiﬁc workﬂow shown in Fig. 4. The
process begins by retrieving microarray experiments that are stored as ﬁles in the Grid ﬁle system and preprocessing
them in two parallel branches based on the platform used. A feature selection stage is then performed in each of
these branches to extract the most informative genes. At the ﬁnal step, the results of the two parallel subprocesses
are combined in an analysis/biomarker discovery task that also uses the results returned by the Semantic Mediator
based on the MO-expressed query for the patients’ clinical data. This workﬂow, which implements a methodology
linking microarrays and classical clinical data and used in biomarker discovery, illustrates the ability of the ACGT
platform to repeat complex analyses on an evolving population of patients, ranging from data retrieval and integration,
normalization, to analysis and results presentation.
3. Lessons learnt, experiences gained
The exploitation of a broad and complex European Commission collaborative project is a multi-dimensional prob-
lem with many challenges as well as opportunities. The experience has provided lessons that could provide additional
guidance to others who might decide to work in the broad areas covered by ACGT. In this section we present these
lessons learned covering the development and exploitation of speciﬁc modules) as well as broader aspects of the
project as a whole.
3.1. Technological Approach
The ACGT infrastructure is a complex technical infrastructure to which many diﬀerent partners have contributed.
Such large technical collaborations can only succeed when suﬃcient attention is given to using as much as possible
industry standards. ACGT has done this; however, the infrastructure produced is still rather monolithic due to the per-
vasive use of its Grid middleware. The big advantage of relying on the existing middleware is that it provides standard
solutions to common complex tasks (e.g. delegation of rights, orchestration, resource allocation, etc). In hindsight, a
technological undertaking of the scale of ACGT (with so many contributors) might beneﬁt from a more lightweight
solution. This means that one is burdened with a number of tasks otherwise covered by the middleware, but experience
has shown that not all functionality oﬀered by the complex middleware is strictly necessary in the trial application
domain. On the other hand a lightweight architecture can evolve more dynamically (e.g. adopting new technology)
1124  Anca Bucur et al. / Procedia Computer Science 4 (2011) 1119–1128
Fig. 4: The MCMP workﬂow
over time. Cooperation with a large number of people can also be more eﬃcient if the focus of collaboration is on
interfacing, interoperability and integration in a more loosely coupled architecture. Quality control and acceptance
testing in view of compliance could also beneﬁt from this approach. It should also be noted, that although a more
lightweight (loosely coupled) architectural approach can in practice easily evolve into “a new” heavyweight middle-
ware (as more functionality is shifted to centrally maintained and deployed proprietary components), the potential
reward makes the approach worth investigating.
3.2. Management of clinical research information and building comprehensive datasets
One of the main challenges in carrying out post-genomic research is to eﬃciently have access to all relevant data.
In the context of clinical trials, this data may be scattered geographically and resides in a variety of diﬀerent systems.
The data typically comprises clinical data collected on Case Report Forms (e.g. symptoms, histology, administered
treatment, treatment response), imaging data (e.g. X-Ray, CT, MR, Ultrasound), genomic data (e.g. microarray data),
pathology data and other lab data. Next to that there are many public biomedical databases that are relevant. These
store information about gene and protein sequences, pathways, genomic variation, microarray experiments, medical
literature, tumor antigens, protein domains, metabolites, etc.
In ACGT, users can query a data resource and obtain its RDF schema when it is available within the ACGT
platform. If the data resource is fully integrated into the ACGT platform, the queries are expressed in terms of the
ACGT Master Ontology, otherwise the queries are expressed in terms of the data resources local ontology.
A relevant challenge is dealing with the generality of the ACGT MO versus the speciﬁcity of a (legacy) database
that we need to integrate. The database schema is developed with a speciﬁc concrete goal in mind, while the ACGT
MO intends to be very generic in an attempt to represent the domain of cancer research and management. When trying
to explore a data resource by formulating SPARQL queries using the ACGT MO as a guide, because the ontology
captures such a wide domain, it is very easy to specify a constraint on a term that is not used in the actual data resource,
resulting in an empty solution as response.
Another challenge is related to enabling users to properly understand and use a new data resource. When ﬁrst
encountering a (potentially) useful data resource, users often try to get to understand the data resource by exploring
it. This can be quite cumbersome when the layout of the underlying data source is according to a generic database
scheme. The ObTima database schema is a generic clinical trial schema, almost similar to a meta-schema. For the
uninitiated user, the generic layout is impossible to understand on its own. To understand the setup of the speciﬁc
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clinical trial in the generic layout, one has to descend to the instance level of the data. The cause of this problem
is the lack of a (preferably standardized) description of the content of the data resource aimed at the (human) user.
In addition, there is currently no tool available to help to browse conveniently through the data contained in a data
resource.
The idea of integrating clinical practice and clinical research gets more and more traction. This will have large
consequences such as a higher innovation pace in patient care, and improved patient safety (e.g. due to less duplication
of patient data entry). The context of the ACGT project is clinical research, which has an eﬀect on the way data is
recorded. In clinical practice, the primary and often only purpose for data recording is direct patient care (on a per-
patient basis), and a lot of data is recorded in free text format. Due to the clinical trial requirements (to allow for a
correct and eﬃcient analysis), the data collected is typically structured. When generalizing the ACGT eﬀort to include
data collected in clinical practice, it should be investigated how to integrate free text resources into the environment
(this includes natural language processing, and semantic integration of the results).
Part of the evaluation of the ACGT results, we have investigated how the expertise, and potentially also the tools,
developed in ACGT could be used to support a large real-life multi-centric clinical trials program, such as NeoBIG,
the new research program of the Breast International Group (http://www.breastinternationalgroup.org/).
To suit the ACGT scope, our focus was on the IT needs of the NeoBIG research program, speciﬁcally with respect to
secure privacy-preserving data management and sharing as these are issues at the core of ACGT.
During the study, we have concluded that there is a lot of ACGT expertise that could be used for the NeoBIG
data sharing platform, especially with respect to data storage, management and sharing, and with respect to privacy
and security. At the same time, we understood that while accessing external data out of heterogeneous repositories is
highly relevant, there is also very high value in supporting the research community to deﬁne common methodologies
concerning data management and to build and share comprehensive datasets including all the wealth of data collected
in the trials. The advantage of building such consolidated data sets under a single authority in charge of their main-
tenance is that coherence, adherence to common methodologies, standards and ontologies, and availability can be
ensured. While a solution maintaining all the data at the institutions generating that data is feasible and provides ﬂexi-
bility and scalability, it does not guarantee adherence to the same methodologies, common data models and standards,
or long term maintenance. This makes enabling (long term) use of the combined datasets more diﬃcult.
3.3. Semantic Data Integration
Developing a semantic integration layer for biomedical databases resulted in a quite complex task. The biomedical
domain, and more speciﬁcally, the cancer-related clinical trials domain, evolves at a surprisingly high rate. We found
out that, during the four and a half years that the project lasted, new requirements appeared, or initial requirements
had to suﬀer modiﬁcations, simply because the biomedical ﬁeld had new needs. We found it was crucial to adopt
highly ﬂexible designs for our tools, so that they could be adapted to the new needs without requiring deep changes in
the code. Due to the extension and the rich feature nature of the tools to develop, it was necessary to adopt third party
tools or APIs available for the research community. Special care must be taken when selecting what tools to use, since
lack of documentation or support can seriously aﬀect development.
3.4. Data Analysis Processes
The ACGT system strives to integrate all steps from the collection and management of various kinds of data in a
trial up to the statistical analysis by the researcher. However, the more powerful these environments become, the more
important it is to guide the user in the complex task of constructing appropriate workﬂows. This is particularly true
for the case of workﬂows which encode a data mining tasks, which are typically much more complex and in a more
constant state of frequent change than workﬂows in business applications. From the ACGT project, we learned that
[13]:
1. The construction of data mining workﬂows is an inherently complex problem when it is based on input data
with complex semantics, as it is the case in clinical and genomic data.
2. Because of the complex data dependencies, copy and paste is not an appropriate technique for workﬂow reuse.
3. Standardization and reuse of approaches and algorithms works very well on the level of services, but not on the
level of workﬂows. While it is relatively easy to select the right parameterization of a service, making the right
connections and changes to a workﬂow template is quickly getting quite complex, such that user ﬁnds it easier
to construct a new workﬂow from scratch.
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4. Workﬂow reuse only occurs when the initial creator of a workﬂow describes the internal logic of the workﬂow
in detail. However, most workﬂow creators avoid this eﬀort because they simply want to “solve the task at
hand”.
Thus, the situation of having a large repository of workﬂows to choose the appropriate one from, which is often
assumed in existing approaches for workﬂow recommendation systems, may not be very realistic in practice.
While a multitude of tools for data mining, bioinformatics, and statistics on clinical data exists, the question of
quality control and standardization, as well as ease of use and reusability, remains largely unanswered yet.
In the business process management community, pattern-based approaches for facilitating reuse have been pro-
posed, e.g. by the deﬁnition of workﬂow patterns that describe the control-ﬂow perspective of workﬂow systems [14]
based on business process modeling formalisms (including BPMN) and business process execution languages (includ-
ing BPEL). Next to BPMN, also UML 2.0 Activity Diagrams have been proposed as notations that are compatible
with workﬂow patterns [15]. Process patterns have many advantages [16]: BPM processes serve as both the speciﬁca-
tion and the source code. The modeled processes become the solutions deployed and provide a simple communication
tool between end-users, business analysts, developers and the management.
To bridge the gap between providing single tools and the knowledge of how to make good use of these tools to
properly answer a biomedical research question, we propose support for a pattern based approach for data mining [17].
A data mining pattern can be viewed as template for a concrete data mining workﬂow. It acts as a formalized common
language between data mining experts and biomedical researchers. It contains not only a reusable workﬂow template,
but also a description of the requirements, assumptions, and steps that need to be fulﬁlled to apply the generic data
mining solution to a speciﬁc problem. It thus describes a data mining solution not only syntactically (which steps need
to be executed) but also semantically (when does it make sense to apply the solution and what result can one expect?).
In future work, we intend to demonstrate that data mining process patterns provide a simple technique to shorten the
learning curve and improve productivity and quality of the analysis processes, as they are simple to understand, learn
and apply immediately.
3.5. Security and Data Protection
Compliance to trial related legislation, especially to the data protection laws, is a critical success factor for any
research-network. ACGT has expended considerable eﬀort in order to automate achieving this compliance, for exam-
ple through the founding of Center for Data Protection (https://cdp.custodix.com/) for establishing necessary
contracts and with tools such as CAT (Custodix Anonymisation Tool) that ease the anonymization of the data.
ACGT has shown us, that investing in achieving compliance by default (without speciﬁc eﬀort or much expertise
from the end-users) with ﬁxed procedures is a must for long term success and smooth operations. In view of the
experience, one could suggest that this requirement should be valued very high when making technological choices.
3.6. User empowerment and Community building
In terms of deploying the ACGT infrastructure and resources in end-user environments consortium exploitation
eﬀorts have highlighted a number of issues that merit speciﬁc attention by similar eﬀorts in the future. They are the
following:
• Not enough infrastructure and services in place: the lack of enough related end-user oriented modules in ACGT
is believed to be one of the factors that have hindered its deployment in actual working environments. In
particular, the ’completeness’ and consistency of the available set of end user services has not been what is
required to support existing workﬂows and tasks in end user partner environments. While considerable eﬀort
was spent in the last year to deﬁne scenarios that represent actual tasks and workﬂows that make sense to end
users (doctors, researchers, etc.). these were still ’fragmented’ being able to support only simple operations.
• Opt-in versus Opt-out and the anti spam laws: The ACGT Management Board decided to adopt a conservative
approach in all its mailing and communication eﬀorts. Opt-in rather than opt-out policies were followed. As a
consequence, circulation and site visit ﬁgures were rather low. It is felt that the failure of the ACGT competition
to attract suﬃcient interest was also partly due to this policy which should not be adopted by similar projects.
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• Continued support of ACGT infrastructure: A number of contacted third parties expressed this concern at
various points in time. While we are not able to ascertain to what degree this has acted as a true deterrent to
adoption, this is certainly an important concern that must be addressed before successful uptake can be expected.
• Intellectual property: IP-issues tend to be a hindering factor in data exchange: On the one hand participating
clinicians have serious reservations against sharing (raw) patient data as their possession is an important (and
not always legally protected) factor in scientiﬁc competition. On the other hand patients’ (sometimes eco-
nomic) interests in the outcome of the research are not always suﬃciently covered by trial setups and results’
exploitation. ACGT has developed guidelines for bringing decision makers into the position to allow patients
and clinicians proper participation in the exploitation process. This work can serve as a basis for European
project managers in the E-health area to identify intellectual property issues in an early stage of the project’s
lifecycle
4. Conclusions
When launched back in 2006, the ACGT project aimed at providing clinical researchers with an infrastructure
that would support the requirements of modern clinical trials. At the same time there were a number of projects that
aim at developing grid-based infrastructure for post-genomic cancer clinical trials, the most advanced of which are
NCI’s caBIG (Cancer Biomedical Informatics Grid, https://cabig.nci.nih.gov/) in the USA and CancerGrid
(http://www.cancergrid.org/) in the UK. The overall approach in those projects was somewhat diﬀerent from
the one in ACGT. In caBIG, the bottom-up, technology-oriented, approach was chosen, in which the focus was put
on the integration of a large number of analysis tools but with weak concern on data privacy issues. CancerGrid on
the other hand addresses the very needs of the British clinical community. In contrast, the ACGT project was focused
on the development of a pan-european system that is driven by current demands from clinical practice. With two
on-going international clinical trials actually conducted in the framework of the project, the approach was top-down,
with clinicians’ and biomedical data analysts’ needs at the heart of all technical decisions, considering data privacy
issues as central as data analysis needs.
In this user driven endeavor the technical concerns raised by the multiplicity and heterogeneity of user require-
ments demanded state of the art methodologies and technologies. In the ACGT work plan the employment of ontolo-
gies and metadata annotations and the realization of intelligent higher level services were the primary implementation
targets. Five years after the launch of the project the consensus among the consortium is that we have made signiﬁcant
progress towards the initial objectives. Some of (mostly technological) decisions made may look suboptimal or have
been superseded by today’s oﬀerings (e.g. the rise of cloud computing replacing the Grid) but the methodology and
the core design principles remain valid. The security framework, the ontology driven approach, the emphasis on sim-
plifying researchers’ daily work focusing on user-friendliness, etc. are of paramount importance in similar endeavors
in contemporary applied research and science.
On the other hand we acknowledge the fact that the ACGT platform is still lacking when considered for everyday
use in a production level environment. Due to the very strict requirements for a production-level system, with available
documentation and user support, commercial deployment and long term maintenance, we have concluded that current
ACGT solutions cannot be directly used e.g. for NeoBIG, however some of them could be part of a further targeted
solution. For these reasons we are continuing our eﬀorts in the context of follow up R&D projects, such as the
INTEGRATE, a project that aims to build an environment that supports a large and multidisciplinary biomedical
community ranging from basic, translational and clinical researchers to the pharmaceutical industry to collaborate,
share data and knowledge, and build and share predictive models for response to therapies, with the end goal of
improving patient outcome. The infrastructure and tools developed by the INTEGRATE project will support BIG to
promote in the clinical community new methodologies and deﬁne standards concerning the collection, processing,
annotation and sharing of data in clinical research and improve the reproducibility of results of clinical trials.
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